Opinion on Drug Delivery in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Will contraceptive patches challenge the pill?

Although the contraceptive pill has been hugely successful, remembering to take it every day can be a problem. Alternative delivery methods such as implants and injections, meanwhile, have proved unpopular. The contraceptive patch could fill the middle ground, potentially cutting unwanted pregnancies - but will it? Datamonitor women's health analyst Jane Richardson cuts through the hype...

Published By Datamonitor
28 Mar 2002
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
CommentWire
CommentWire

UK vaccination: coverage falls but the threat remains

Following a fall in MMR coverage after the 1998 Wakefield report linking the triple jab to autism, new research suggests it could be difficult to restore pre-scare vaccine coverage levels, leaving the country open to a potentially serious outbreak of preventable diseases. Parents need access to full clinical data on vaccines so they can make a properly informed decision.

Published By Datamonitor
25 Aug 2004
CommentWire
CommentWire

Teva: increasing penetration in southern Europe

Generics giant Teva [TEVA] has agreed to acquire Italian generics company Dorom from Pfizer for $80 million, becoming the largest generics company in Italy. Over the longer term, continued geographical expansion will counteract Teva's recent share price drop and reduce the company's dependence on key branded products like Copaxone.

Published By Datamonitor
19 Aug 2004
Expert View
Expert View

Targeted therapy cancer brands to achieve sales of over $42 billion by 2017

Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017. Eight more marketed brands are set to achieve blockbuster status over the 10-year forecast period, driven by the persistent unmet need that still exists across a number of tumor types.

Published By Datamonitor
03 Oct 2008
CommentWire
CommentWire

Stem cell research: Europe seizes the advantage

The House of Lords committee was set up to review the ethical implications of allowing human embryonic cloning for research into degenerative diseases. Despite fierce campaigning by 'pro-life' groups, it came out in favor. Particularly after the recent restrictions imposed in the US, a 'reverse brain drain' of investment from the US to Europe could be on the cards.

Published By Datamonitor
28 Feb 2002
CommentWire
CommentWire

Sanofi-Aventis: Nasacort catches up with competitors

Nasacort, a nasal steroid used in allergic rhinitis, has been approved for the treatment of children aged two to five years old. Although the breadth of its label is now similar to that of some of its competitors, Datamonitor does not expect that the expanded approval will have a significant impact on sales.

Published By Datamonitor
24 Sep 2008
CommentWire
CommentWire

Sanofi-Aventis: Ambien strategy falters at key hurdle

News that the FDA has not yet given full approval for a new formula of Sanofi-Aventis's Ambien throws a spanner in the works of the company's bid to prevent generic erosion of the blockbuster's revenues. It is a familiar story in big pharma these days: the sector needs to find a long-term solution to the generic threat by focusing on the R&D opportunities offered in the biotech sector.

Published By Datamonitor
13 Apr 2005
CommentWire
CommentWire

Roche: synergies provide boost despite vitamin deficiency

Roche's acquisition of Disetronic looks set to boost its presence in the diabetes market. But its enthusiasm will be tempered by news that the spin-off of its vitamin business will reap lower rewards than expected, while further funds must be set aside to settle price rigging claims. Even so, Roche and Disetronic will enjoy some valuable synergies.

Published By Datamonitor
12 Feb 2003
CommentWire
CommentWire

Roche: cautious start to metabolic syndrome development

JTT-705, which Roche is to license from Japan Tobacco, is a novel anti-dyslipidemic that will further enhance the company's cardiovascular risk factor offering. This latest move could ultimately place Roche in a potentially advantageous position in the growing metabolic syndrome market, though it marks only the start of a long process to increase its currently meager offering in this field.

Published By Datamonitor
21 Oct 2004

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.